Advertisement

Cause of death and risk factors for mortality in AA amyloidosis: A French retrospective study

  • Alexandre Terré
    Affiliations
    Sorbonne University, AP-HP, Tenon hospital, Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris GRC -28, France
    Search for articles by this author
  • Samuel Deshayes
    Affiliations
    Normandie Univ, UNICAEN, CHU de Caen Normandie, Department of Internal Medicine, Caen 14000, France
    Search for articles by this author
  • Léa Savey
    Affiliations
    Sorbonne University, AP-HP, Tenon hospital, Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris GRC -28, France
    Search for articles by this author
  • Gilles Grateau
    Affiliations
    Sorbonne University, AP-HP, Tenon hospital, Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris GRC -28, France

    Inserm UMRS_933, et laboratoire de génétique, Trousseau hospital, AP-HP, Faculté de médecine - Sorbonne University, Paris, France
    Search for articles by this author
  • Sophie Georgin-Lavialle
    Correspondence
    Corresponding author at: Sorbonne University Assistance Publique-Hôpitaux de Paris. Centre de référence des maladies auto-inflammatoires et des amyloses inflammatoires (CEREMAIA), Department of Internal medicine, Tenon hospital, 20, rue de la Chine, Paris 75020, France.
    Affiliations
    Sorbonne University, AP-HP, Tenon hospital, Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris GRC -28, France

    Inserm UMRS_933, et laboratoire de génétique, Trousseau hospital, AP-HP, Faculté de médecine - Sorbonne University, Paris, France
    Search for articles by this author
Published:August 14, 2020DOI:https://doi.org/10.1016/j.ejim.2020.08.012

      Highlights

      • AA amyloidosis epidemiology is evolving with a decrease of cases caused by inflammatory rheumatism.
      • Infections are now the most frequent cause of death of patients suffering from AA amyloidosis.
      • Several factors are associated with the mortality in AA amyloidosis, such as the cause of the amyloidosis, or the presence of a nephrotic syndrome.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Westermark G.T.
        • Fändrich M.
        • Westermark P.
        AA amyloidosis: pathogenesis and targeted therapy.
        Annu Rev Pathol. 2015; 10: 321-344
        • Lachmann H.J.
        • Goodman H.J.B.
        • Gilbertson J.A.
        • Gallimore J.R.
        • Sabin C.A.
        • Gillmore J.D.
        • et al.
        Natural history and outcome in systemic AA amyloidosis.
        N Engl J Med. 2007; 356: 2361-2371
        • Lane T.
        • Pinney J.H.
        • Gilbertson J.A.
        • Hutt D.F.
        • Rowczenio D.M.
        • Mahmood S.
        • et al.
        Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre.
        Amyloid. 2017; 24: 162-166
        • Stankovic Stojanovic K.
        • Georgin-Lavialle S.
        • Poitou C.
        • Buob D.
        • Amselem S.
        • Grateau G.
        • et al.
        AA amyloidosis is an emerging cause of nephropathy in obese patients.
        Eur J Intern Med. 2017; 39: e18-e20
        • Gertz M.A.
        • Comenzo R.
        • Falk R.H.
        • Fermand J.P.
        • Hazenberg B.P.
        • Hawkins P.N.
        • et al.
        Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.
        Am J Hematol. 2005; 79: 319-328
      1. Modern Applied Statistics with S, 4th ed [Internet]. [cited 2019 Nov 21]. Available from: http://www.stats.ox.ac.uk/pub/MASS4/.

        • Thomas B.
        • Matsushita K.
        • Abate K.H.
        • Al-Aly Z.
        • Ärnlöv J.
        • Asayama K.
        • et al.
        Global cardiovascular and renal outcomes of reduced GFR.
        J Am Soc Nephrol JASN. 2017; 28: 2167-2179
        • Papa R.
        • Lachmann H.J.
        Secondary, AA, amyloidosis.
        Rheum Dis Clin North Am. 2018; 44: 585-603
        • Palladini G.
        • Riva E.
        • Basset M.
        • Russo F.
        • Milani P.
        • Pasquinucci E.
        • et al.
        Prognostication of survival and progression to dialysis in AA amyloidosis.
        Amyloid. 2017; 24: 136-137
        • D'Hoore W.
        • Sicotte C.
        • Tilquin C.
        Risk adjustment in outcome assessment: the Charlson comorbidity index.
        Methods Inf Med. 1993; 32: 382-387